Anima Biotech
Small-molecule mRNA Drug Discovery
StartupAnima Biotech is a Ramat Gan-based startup in the Health Tech & Life Sciences sector, established in 2014. Small-molecule mRNA Drug Discovery. The company has raised a total of $30M across 1 funding round, currently at the Seed stage. Anima Biotech was founded by Yochi Slonim, M.Sc. and Zeev Smilanski, Ph.D.. Key investors include National Institute of Health (NIH). The company has 51-200 employees. Core technologies: Platforms & Interfaces, Software, Biologicals, Molecules, Artificial Intelligence.
With $30M in total funding, Anima Biotech is a Seed-stage company operating in Health Tech & Life Sciences. The company follows a B2B business model. Product stage: Clinical Trial. The company holds 1 patent.
- StageSeed
- ProductClinical Trial
- ModelB2B
- Employees51-200
- HQRamat Gan
- DistrictCenter District
- Last Round$30M
- National Institute of Health (NIH)
Yochi Slonim, M.Sc.Co-Founder & CEO
Zeev Smilanski, Ph.D.Co-Founder & CTO
18 articles covered by sources including www.genengnews.com,
news.abbvie.com,
www.globenewswire.com,
finance.yahoo.com,
www.pharmasalmanac.com.
What does Anima Biotech do?
Anima Biotech is advancing mRNA Lightning, a novel platform for the discovery of selective small-molecule mRNA drugs and their mechanisms of action. The company combines high-scale phenotypic screening that automates millions of experiments in live mRNA biology with MOAi technology using artificial intelligence to elucidate the mechanism of action of active molecules. This level of automation of phenotypic screening of mRNA modulators together with its AI-driven MOA elucidation has enabled Anima Biotech to develop a broad pipeline across 18 different discovery programs in various therapeutic areas. Anima's wholly owned pipeline programs are in fibrosis (collagen I mRNA biology modulators, preclinical stage in lung fibrosis and applicable across many fibrotic diseases), oncology (c-Myc mRNA biology modulators and mutation-agnostic mKras mRNA biology modulators), and neuroscience (Tau; Alzheimer's disease and pain; Nav1.7 mRNA biology modulators). In addition, Anima established strategic collaborations with the pharmaceutical industry in partnered programs including Lilly, Takeda Pharmaceuticals, and Abbvie.
How much funding has Anima Biotech raised?
Anima Biotech has raised $30M in total funding across 1 rounds. The company is currently at the Seed stage. Key investors include National Institute of Health (NIH).
Who founded Anima Biotech?
Anima Biotech was founded in 2014 by Yochi Slonim, M.Sc. (Co-Founder & CEO), Zeev Smilanski, Ph.D. (Co-Founder & CTO).
What sector is Anima Biotech in?
Anima Biotech operates in Health Tech & Life Sciences, Pharma & Medical Biotechnology, Drugs Discovery & Development, with core technologies in Platforms & Interfaces, Software, Biologicals, Molecules, Artificial Intelligence. Target customers: Healthcare & Life Sciences, Life Sciences, Pharmaceuticals.
Where is Anima Biotech located?
Anima Biotech is based in Shoham St 2, Ramat Gan, Israel, Center District. The company also has offices abroad.